Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Trazodone is a widely prescribed atypical antidepressant belonging to the class of serotonin antagonist and reuptake inhibitors (SARIs). Its molecular formula is C19H25ClN4O, and it carries the CAS registry number 16725-83-0. Originally developed in the late 1960s by Angelini Pharma, Trazodone was introduced to the market as a treatment for major depressive disorder. Unlike many other antidepressants that primarily function through monoamine oxidase inhibition or selective serotonin reuptake inhibition, Trazodone operates through a unique dual mechanism: it blocks serotonin 5-HT2A receptors while simultaneously inhibiting the reuptake of serotonin into presynaptic neurons. This specific pharmacological profile helps restore the balance of neurotransmitters in the brain, alleviating symptoms of depression such as persistent sadness, loss of interest, and fatigue.
Beyond its primary indication for depression, Trazodone is frequently utilized off-label for managing insomnia due to its potent sedative effects, which stem from its antagonism of histamine H1 receptors. It is also commonly prescribed to treat anxiety disorders and to mitigate sexual side effects caused by other antidepressants like SSRIs. Clinically, it is available in various oral formulations, including immediate-release tablets and extended-release capsules, allowing for flexible dosing strategies tailored to individual patient needs. Common side effects include drowsiness, dry mouth, dizziness, and headache, though serious adverse events like priapism, while rare, require immediate medical attention. The drug is generally considered safe for long-term use under medical supervision, with a lower risk of causing significant weight gain compared to older tricyclic antidepressants. As a versatile therapeutic agent, Trazodone remains a cornerstone in psychiatric pharmacotherapy, offering a valuable option for patients who do not respond adequately to first-line treatments or who require additional sleep support alongside mood stabilization. Its enduring presence in clinical practice underscores its efficacy and safety profile in modern medicine.